

Specialty Guideline Management

Zegfrovy

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Zegfrovy	sunvozertinib

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications¹

Zegfrovy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Compendial Use²

Recurrent, advanced, or metastatic NSCLC, EGFR exon 20 positive

All other indications are considered experimental/investigational and not medically necessary.

Documentation

Submission of the following information is necessary to initiate the prior authorization review: EGFR mutation testing results.

Coverage Criteria

Non-small Cell Lung Cancer (NSCLC)¹

Authorization of 12 months may be granted for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation when the following criteria is met:

- The requested medication will be used as a single agent for recurrent, advanced, or metastatic disease with progression on or after platinum-based chemotherapy.

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

References

1. Zegfrovy [package insert]. Shanghai, China: Dizal (Jiangsu) Pharmaceutical Co., Ltd.; July 2025.
2. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed July 14, 2025.